Limosilactobacillus reuteri

Source: Wikipedia, the free encyclopedia.
(Redirected from
Lactobacillus reuteri
)

Limosilactobacillus reuteri
Scientific classification Edit this classification
Domain: Bacteria
Phylum: Bacillota
Class: Bacilli
Order: Lactobacillales
Family: Lactobacillaceae
Genus: Limosilactobacillus
Species:
L. reuteri
Binomial name
Limosilactobacillus reuteri
Zheng et al., 2020
Synonyms
  • Lactobacillus reuteri Kandler et al., 1980
  • Lactobacillus fermentum biotype II Reuter, 1965

Limosilactobacillus reuteri is a

lactic acid bacterium found in a variety of natural environments, including the gastrointestinal tract
of humans and other animals. It does not appear to be pathogenic and may have health effects.

Discovery

At the turn of the 20th century, L. reuteri was recorded in scientific classifications of

Lactobacillus fermentum. In the 1960s, further work by microbiologist Gerhard Reuter, for whom the species eventually was named, reclassified the species as L. fermentum biotype II.[2]

Significant differences were found between biotype II and other biotypes of L. fermentum, to the point that in 1980 it was identified as a distinct species and the formal species identity, L. reuteri, was proposed.[3] In April 2020, L. reuteri was reassigned to the genus Limosilactobacillus.[4]

Prevalence

Limosilactobacillus reuteri is found in a variety of natural environments. It has been isolated from many foods, especially meats and dairy products.

chickens,[8] pigs,[9] and rodents.[10] It is the only species to constitute a "major component" of the Lactobacillus species present in the gut of each of the tested host animals,[11] and each host seems to harbor its own specific strain of L. reuteri.[10][12] It is possible that L. reuteri contributes to the health of its host organism in some manner.[13]

Limosilactobacillus reuteri is present as a dominant member of

glutamate, improve bread quality. [14]

Effects

Antimicrobial

Limosilactobacillus reuteri is known to produce reuterin,[15] reutericin 6[16] and reutericyclin.[17][18]

Reuterin

In the late 1980s,

M, the HPA dimer was predominant. However, at concentrations relevant for biological systems, HPA hydrate was the most abundant, followed by the aldehyde form.[21]

Reuterin inhibits the growth of some harmful

fungi and protozoa.[22] Researchers found that L. reuteri can secrete sufficient amounts of reuterin to achieve the desired antimicrobial effects. Furthermore, since about four to five times the amount of reuterin is needed to kill "good" gut bacteria (i.e. L. reuteri and other Lactobacillus species) as "bad", this would allow L. reuteri to remove gut invaders without harming other gut microbiota.[13]

Some studies questioned whether reuterin production is essential for L. reuteri's health-promoting activity. The discovery that it produces an antibiotic substance led to a great deal of further research. In early 2008, L. reuteri was confirmed to be capable of producing reuterin in the gastrointestinal tract, improving its ability to inhibit the growth of E. coli.[23]

The gene cluster controlling the biosynthesis of reuterin and

cobalamin in the L. reuteri genome is a genomic island acquired from an anomalous source.[24]

Clinical results in humans

Although L. reuteri occurs naturally in humans, it is not found in all individuals. Dietary supplementation can sustain high levels of it in those with deficiencies. Oral intake of L. reuteri has been shown to effectively colonize the intestines of healthy individuals. Colonization begins within days of ingestion, although levels drop months later if intake is stopped.[25] L. reuteri is found in breast milk.[26] Oral intake on the mother's part increases the amount of L. reuteri present in her milk, and the likelihood that it will be transferred to the child.[27]

Safety

Manipulation of gut microbiota is a complex process that may cause bacteria-host interactions.

bacteremia, fungemia and sepsis, potentially fatal infections, in children with compromised immune systems or who are already critically ill.[31]

Intestinal health

One of the better documented effects of L. reuteri is a significant reduction of symptom duration in pediatric

intestinal motility.[38]

Limosilactobacillus reuteri may be effective treating necrotizing enterocolitis in preterm infants. Meta-analysis of randomized studies suggests that L. reuteri can reduce the incidence of sepsis and shorten the required duration of hospital treatment in this population.[39]

Limosilactobacillus reuteri is an effective treatment against infant

simethicone[43] or placebo.[44]
However, colic is still poorly understood, and it is not clear why or how L. reuteri ameliorates its symptoms. One theory holds that affected infants cry because of gastrointestinal discomfort; if this is the case, it is plausible that L. reuteri somehow acts to lessen this discomfort, since its primary residence is inside the gut.

Gastric health

Limosilactobacillus reuteri have a pronounced anti-helicobacter activity and its use as adjuvant therapy of H. pylori in children appears to be very promising, especially in the case of detection of infection with H. pylori with no absolute indication of eradication.[45]

Growing evidence indicates L. reuteri is capable of fighting the gut

peptic ulcers and is endemic in parts of the developing world. One study showed dietary supplementation of L. reuteri alone reduces, but does not eradicate, H. pylori in the gut.[46] Another study found the addition of L. reuteri to omeprazole therapy dramatically increased (from 0% to 60%) the cure rate of H. pylori-infected patients compared to the drug alone.[47] Yet another study showed that L. reuteri effectively suppressed H. pylori infection and decreased the occurrence of dyspeptic symptoms, although it did not improve the outcome of antibiotic therapy.[48]

Llimosilactobacillus reuteri has the potential to suppress H. Pylori infection and may lead to an improvement of H. Pylori-associated gastrointestinal symptoms,

antibiotics resistance, L. reuteri may be a great alternative treatment for H. pylori causing fewer side effects than antibiotics.[52]

Oral health

Limosilactobacillus reuteri may be capable of promoting dental health, as it has been proven to kill

mouths are colonized with L. reuteri (via dietary supplementation) have significantly less S. mutans.[53]
Since these studies were short-term, it is not known whether L. reuteri prevents tooth decay. However, since it is able to reduce the numbers of an important decay-causing bacterium, this would be expected.

gum bleeding, plaque formation and other gingivitis-associated symptoms compared with placebo after chewing gum containing L. reuteri.[54]

Bone density

Lactobacillus reuteri and other probiotics may influence the

gut microbiome in ways that protect against bone loss
, common in post-menopausal women. [55][56][57][58][59]

General health

By protecting against many common infections, L. reuteri promotes overall wellness in both children and adults.

randomized studies in child care centers have found L. reuteri-fed infants fall sick less often, require fewer doctor visits and are absent fewer days from the center compared to placebo and to the competing probiotic Bifidobacterium lactis.[60]

Similar results have been found in adults; those consuming L. reuteri daily end up falling ill 50% less often, as measured by their decrease use of sick leave.[61]

Results in animal models

Scientific studies that require harming the subjects (for example, exposing them to a dangerous virus) cannot be conducted in humans. Therefore, many of L. reuteri's benefits have been studied only in different animal species, such as pigs and mice.

In general, animal studies on L. reuteri are done using the species-specific strain of the bacterium.

Protection against pathogens

Limosilactobacillus reuteri confers a high level of resistance to the

Salmonella typhimurium, halving mortality rates in mice.[62] The same is true for chickens[63]
and turkeys; L. reuteri greatly moderates the morbidity and mortality caused by this dangerous food-borne pathogen.

Limosilactobacillus reuteri is effective in stopping harmful strains of

E. coli from affecting their hosts. A study performed in chickens showed L. reuteri was as potent as the antibiotic gentamicin in preventing E. coli-related deaths.[64]

The protozoic parasite Cryptosporidium parvum causes severe watery diarrhea, which can become life-threatening in immunocompromised (as in individuals infected with HIV) patients. L. reuteri is known to lessen the symptoms of C. parvum infection in mice[65] and pigs.[13]

Some protective effect against the yeast

L. casei.[66]

Body weight and growth

In juvenile commercial

commercial farms are generally less healthy (and therefore weigh less) than their counterparts born and bred in cleaner spaces. In turkeys, for example, this phenomenon is known as "poult growth depression", or PGD.[67]

Supplementing the diets of these young animals with L. reuteri helps them to largely overcome the stresses imposed by unhealthy environs. Commercial turkeys fed L. reuteri from birth had nearly a 10% higher adult body weight than their peers raised in the same conditions.

antibiotics in improving body weight under crowded conditions.[69]

The mechanism by which L. reuteri is able to support healthy growth is not entirely understood. It possibly serves to protect against illness caused by S. typhimurium and other pathogens (see above), which are much more common in crowded commercial farms. However, other studies found that it can help when the growth depression is caused entirely by a lack of

dietary protein, and not by contagious disease.[70] This raises the possibility that L. reuteri somehow improves the intestines' ability to absorb and process nutrients.[13]

Chemical and trauma-induced injury

Treating

colonic tissue from rats with acetic acid causes an injury similar to the human condition ulcerative colitis. Treating the injured tissue with L. reuteri immediately after removing the acid almost completely reverses any ill effects,[71]
leading to the possibility that L. reuteri may be beneficial in the treatment of human colitis patients.

In addition to its role in

bacterial "translocation", can lead to lethal conditions such as sepsis. In humans, translocation is more likely to occur following such events as liver injury and ingestion of some poisons. In rodent studies, L. reuteri was found to greatly reduce the amount of bacterial translocation following either the surgical removal of the liver[73] or injection with D-galactosamine,[74]
a chemical which causes liver damage.

The anticancer drug methotrexate causes severe enterocolitis in high doses. L. reuteri greatly mitigates the symptoms of methotrexate-induced enterocolitis in rats, one of which is bacterial translocation.[75]

Links to fat in diet of mice, and reversible symptoms of behavioral abnormalities

In mice, the absence of L. reuteri has been causally linked to maternal diet.

autism in humans.[72] These symptoms were reversible by supplementing L. reuteri.[72]

References

  1. ^ Orla-Jensen, S. 1919. The lactic acid Bacteria. Det Kongelige Danske Videnskasbernes Selskab. Naturvidenskabelige mathematiske Afdeling, NS 8.5.2
  2. ^ a b Reuter G. (1965). "Das vorkommen von laktobazillen in lebensmitteln und ihr verhalten im menschlichen intestinaltrakt". ZBL. Bak. Parasit. Infec. Hyg. I Orig. 197 (S): 468–87.
  3. ^ Kandler O.; Stetter K.; Kohl R. (1980). "Lactobacillus reuteri sp. nov. a new species of heterofermentative lactobacilli". ZBL. Bakt. Hyg. Abt. Orig. C1: 264–9.
  4. PMID 32293557
    .
  5. ^ Lerche M, Reuter G (1965). "Das vorkommen aerob wachsender grampositiver stabchen des genus Lactobacuillus beijerinck im darminhalt erwachsener menchen". ZBL. Bak. Parasit. Infec. Hyg. I Orig. 185 (S): 446–81.
  6. ^ Dellaglio F, Arrizza FS, Leda A (1981). "Classification of citratefermenting lactobacilli isolated from lamb stomach, sheep milk, and pecorino romano cheese". ZBL. Bakt. Hyg. Abt. Orig. C2: 349–56.
  7. PMID 8468264
    .
  8. doi:10.1016/s0723-2020(85)80017-5
    .
  9. PMID 7592119
    .
  10. ^
    S2CID 46249658
    .
  11. ^ Mitsuoka T (1992). "The human gastrointestinal tract". In Wood BJB (ed.). The lactic acid bacteria in health and disease. Vol. 1. The lactic acid bacteria. New York: Elsevier Applied Science. pp. 69–114.
  12. ^ Casas IA; Dobrogosz WJ (1997). "Lactobacillus reuteri: An overview of a new probiotic for humans and animals". Microecol Therap. 25: 221–31.
  13. ^
    doi:10.3402/mehd.v12i4.8196
    .
  14. S2CID 52143236
    .
  15. ^
    PMID 3245697
    .
  16. PMID 9039561
    .
  17. PMID 11010877
    .
  18. doi:10.14739/2310-1210.2020.4.208397
    .
  19. doi:10.1039/jr9500000490
    .
  20. ^ Nielsen AT; Moore DW; Schuetze Jr. A. "13C and 1H NMR study of formaldehyde reactions with acetaldehyde and acrolein. Synthesis of 2-(hydroxymethyl)-1,3-propanediol". Pol J Chem. 55: 1393–1403.
  21. S2CID 39296044
    .
  22. PMID 2751282
    .
  23. PMID 18028400
    .
  24. PMID 18487258
    .
  25. doi:10.3109/08910609509141381
    .
  26. doi:10.1203/00006450-200508000-00381
    .
  27. S2CID 71355253
    .
  28. ^
    PMID 26900283
    .
  29. PMID 16762934
    .
  30. PMID 25922398
    .
  31. PMID 27081478
    .
  32. PMID 26991503
    .
  33. PMID 24463209
    .
  34. PMID 9427453
    .
  35. doi:10.1203/00006450-199604001-01111
    .
  36. ^ Romeo MG, Betta P, Oliveri S. (2006) Presented at the 5th Annual meeting of the Italian Society of Perinatal Medicine, Parma, Italy, 15–17 June 2006. Abstract published in J Perinat Med 34(Suppl 1): A9, abstract MSL_24.
  37. ^ Guerrero M, Dohnalek M, Newton P, Kuznetsova O, Ruiz-Palacios G, Murphy T, Calva J, Hilty M, Costigan T., 1st World Congress of Pediatric Infectious Diseases, Dec. 1996, abstract no. 610:45-2.
  38. S2CID 25182003
    .
  39. PMID 26059900
    .
  40. S2CID 3809924
    .
  41. S2CID 26126920
    .
  42. ^ Elena A Kornienko, Natalia I. Parolova, Sergey V. Ivanov, Dmitry S Polev, Pavel A Zykin, Yulia D. Kontratenko, Mikhail M. Zakharchenco (January 16, 2020) "Gastric microbiota and probiotics opportunities in helicobacter pylori eradication in children."
  43. S2CID 2306025
    .
  44. S2CID 207164055
    .
  45. ^ Parolova NI, Kornienko EA, Antonov PV Egorov Mikhail Gorbunov EF, Dmitrienko MA (2015) ) "An innovative approach in the treatment of H. pylori infection in children."
  46. PMID 17695792
    .
  47. S2CID 25834848
    .
  48. S2CID 28856447
    .
  49. ^ Buckley M, Lacey S, Doolan A, Goodbody E, Seamans K (2018), "The effect of Lactobacillus reuteri supplementation in Helicobacter pylori infection: a placebo-controlled, single-blind study." BMC nutrition.
  50. ^ Yang C, Liang L, Pinjing Lv, Liu L, Wang S, Wang Z, Chen Y (2021) “Effects of non-viable Lactobacillus reuteri combining with 14-days standard triple therapy on Helicobacter pylori eradication: A randomized double blind placebo-controlled trial.
  51. ^ Holz C, Busjahn A, Mehling H, Arya S, Boettner M, Habibi H, Lang C, (2014). "Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study". Probiotics & Antimicro. Prot
  52. ^ Mihai C, Mihai BM, Dranga M, Cardoneanu A, Prelipcean CC (2019) “Lactobacillus reuteri – an alternative in the first-line of helicobacter pylori eradication”. Farmacia, Vol. 67, 5
  53. PMID 15282133
    .
  54. PMID 16878680
    .
  55. doi:10.1146/knowable-022222-1
    . Retrieved 8 March 2022.
  56. S2CID 49332819
    .
  57. S2CID 208455504
    . Retrieved 8 March 2022.
  58. PMID 32257552
    .
  59. PMID 33679604
    .
  60. S2CID 1103712
    .
  61. PMID 16274475
    .
  62. ^ Carbajal N, Sriburi A, Carter P, Dobrogosz W, Casas, I. Probiotic administrations of Lactobacillus reuteri protect mice from Salmonella typhimurium infection. Proceedings of the 36th Annual Meeting of the Association for Gnotobiotics. 1998 Jun 14–16; Bethesda (MD): Association for Gnotobiotics; 1998.
  63. Dobrogosz WJ
    . Lactobacillus reuteri: an effective probiotic for poultry and other animals. Lactic acid bacteria, 2nd ed. New York: Marcel Dekker, 1998: 475–518.
  64. PMID 9037704.[permanent dead link
    ]
  65. PMID 8985225
    .
  66. PMID 9317023
    .
  67. ^ Barnes JH (1993). "Evaluating poult growth and productivity during brooding". Turkeys. 41: 23–4.
  68. doi:10.12938/bifidus1996.17.141
    .
  69. ^ Blanchard P, Gill P, Schulze H. Efficacy of Lactobacillus reuteri 1063-IA in pre- and post-weaning pigs. Hertfordshire SG5 4JG (UK): MLC Stotfold Pig Development Unit; 1998. Study Reference No. FF9801.
  70. doi:10.12938/bifidus1996.17.133
    .
  71. PMID 8382837
    .
  72. ^
    PMID 27315483
    .
  73. PMID 7732342
    .
  74. S2CID 37579834
    .
  75. PMID 8690198
    .

External links
Retrieved from "https://en.wikipedia.org/w/index.php?title=Limosilactobacillus_reuteri&oldid=1204635269"